In the limited form, patients usually have disease confined to the respiratory tract (sinusitis, nasal ulceration, or lung nodules) and may have low‑level kidney involvement that does not cause overt renal failure. Recognizing this form early is crucial because untreated disease can progress to the generalized form, which carries a higher risk of organ damage.

Symptoms

Symptoms vary depending on which organ systems are involved. Below is a comprehensive list with brief explanations.

Upper Respiratory Tract

• Chronic sinusitis – persistent nasal congestion, thick purulent discharge, facial pressure.
• Nasal crusting or ulceration – painful sores inside the nostrils, may bleed.
• Epistaxis (nosebleeds) – frequent or severe.
• Otitis media or mastoiditis – ear pain, hearing loss.
• Hoarseness – due to laryngeal involvement.

Lung Involvement

• Cough – dry or productive.
• Hemoptysis – coughing up blood, ranging from streaks to large amounts.
• Shortness of breath – especially on exertion.
• Pleural pain – sharp chest pain that worsens with breathing.
• Radiologic nodules or infiltrates – seen on chest X‑ray/CT.

Kidney (Limited)

• Often asymptomatic; may have microscopic hematuria or mild proteinuria on urine dipstick.

General/Constitutional

• Fatigue, malaise.
• Unexplained weight loss.
• Low‑grade fever.
• Joint or muscle aches (myalgia).

Causes and Risk Factors

The exact trigger for GPA is unknown, but research points to a combination of genetic susceptibility, environmental exposures, and immune dysregulation.

• Autoimmune response – Aberrant activation of neutrophils that release proteinase‑3 anti‑neutrophil cytoplasmic antibodies (PR3‑ANCA), leading to vessel inflammation.
• Genetics – Certain HLA‑DQ and HLA‑DR alleles increase risk.³
• Environmental exposures – Silica dust, occupational inhalants, and possibly chronic nasal colonization with Staphylococcus aureus (linked to higher relapse rates).⁴
• Infections – No direct causation, but infections can precipitate disease flares.
• Smoking – Increases risk of lung involvement and relapse.

Diagnosis

Diagnosing the limited form requires a high index of suspicion because symptoms often mimic common infections or allergic conditions.

Clinical Evaluation

• Detailed history of ENT and respiratory symptoms.
• Physical exam focusing on nasal mucosa, lungs, and kidney signs.

Laboratory Tests

• ANCA testing – PR3‑ANCA (c‑ANCA) is positive in ~80‑90 % of GPA patients; MPO‑ANCA (p‑ANCA) is less common in the limited form.
• Complete blood count (CBC) – may show anemia or leukocytosis.
• Renal function panel – serum creatinine, BUN.
• Urinalysis – microscopic hematuria, mild proteinuria.
• Inflammatory markers – ESR, CRP often elevated.

Imaging

• Chest X‑ray/CT scan – nodules, cavitations, or ground‑glass opacities.
• Sinus CT – mucosal thickening, bone destruction.

Histopathology (Biopsy)

Biopsy of involved tissue (nasal mucosa, lung nodule, or sinus) confirms granulomatous inflammation and necrotizing vasculitis. While not always required if clinical picture and ANCA are classic, a tissue diagnosis helps rule out infection or malignancy.

Diagnostic Criteria

Most clinicians use the 2022 ACR/EULAR GPA classification criteria, which assign weighted points for clinical, serologic, and histologic features. A score ≥5 classifies a patient as having GPA.⁵

Treatment Options

Treatment aims to induce remission (stop active inflammation) and then maintain remission while minimizing drug toxicity.

Induction Therapy

• Glucocorticoids – Prednisone 1 mg/kg/day (max 60 mg) tapered over 4‑6 months. Pulse methylprednisolone (500‑1000 mg IV daily for 3 days) may be used for severe lung disease.
• Rituximab – Anti‑CD20 monoclonal antibody; 375 mg/m² weekly for 4 weeks or 1 g IV on days 1 and 15. Preferred over cyclophosphamide for many patients due to lower long‑term toxicity.⁶
• Cyclophosphamide – Oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2‑3 weeks) for 3‑6 months if rituximab contraindicated.

Maintenance Therapy

• Azathioprine – 2 mg/kg/day.
• Methotrexate – 15‑25 mg weekly (if renal function normal).
• Mycophenolate mofetil – 1‑1.5 g twice daily (alternative).
• Rituximab – 500 mg IV every 6 months for 2‑4 years (based on B‑cell monitoring).
• Low‑dose prednisone (≤5 mg/day) is often continued for the first year.

Adjunctive Measures

• Trimethoprim‑Sulfamethoxazole (TMP‑SMX) – 800/160 mg twice weekly reduces relapse risk, especially in PR3‑ANCA positive patients.⁷
• Proton pump inhibitor or bone‑protective agents – to mitigate steroid‑induced gastritis and osteoporosis.
• Vaccinations – Influenza, pneumococcal, COVID‑19 (non‑live); vaccinate before immunosuppression when possible.

Procedures

• Bronchoscopy – for diagnostic sampling of lung lesions.
• Sinus surgery – May be required for chronic sinusitis or to obtain tissue for biopsy.
• Plasma exchange – Reserved for severe pulmonary hemorrhage or rapidly progressive glomerulonephritis (rare in limited form).

Living with Wegener’s Granulomatosis (Granulomatosis with Polyangiitis) – Limited Form

Even after remission, GPA requires ongoing self‑management.

Medication Adherence

• Take immunosuppressants exactly as prescribed; do not stop abruptly.
• Use a weekly pill organizer or medication‑tracking app.

Monitoring

• Quarterly blood work (CBC, liver/kidney function, CRP/ESR) during the first year.
• ANCA titers can help predict relapse, but trends must be interpreted with clinical context.
• Annual urinalysis and blood pressure check to catch early kidney involvement.

Lifestyle Adjustments

• Smoking cessation – reduces lung disease and relapse risk.
• Balanced diet – high in calcium and vitamin D; limit sodium to protect kidneys.
• Regular exercise – low‑impact activities (walking, swimming) improve stamina and bone health.
• Stress management – mindfulness, yoga, or counseling can help with chronic disease coping.

Infection Prevention

• Practice hand hygiene and avoid crowds during flu season.
• Promptly treat any respiratory infection; inform clinicians about your immunosuppressed status.
• Consider prophylactic TMP‑SMX if you have frequent urinary or respiratory infections.

Patient Support

• Join patient advocacy groups such as the Vasculitis Foundation for education and community.
• Keep a symptom diary to discuss changes with your rheumatologist.

Prevention

Because GPA’s exact cause is unknown, primary prevention is limited. However, certain measures can lower the risk of disease activation or relapse.

• Avoid occupational exposure to silica or dust; use proper protective equipment.
• Quit smoking and limit alcohol intake.
• Maintain up‑to‑date vaccinations before starting immunosuppression.
• Promptly treat chronic sinus infections and consider ENT evaluation for persistent nasal crusting.
• Adhere to prophylactic TMP‑SMX if prescribed.

Complications

If left untreated or poorly controlled, the limited form can progress to generalized GPA or cause organ‑specific damage.

• Renal failure – due to silent glomerulonephritis progressing to crescentic disease.
• Severe pulmonary hemorrhage – life‑threatening bleeding.
• Upper airway stenosis – scar tissue causing breathing difficulty.
• Secondary infections – opportunistic bacterial, fungal, or viral infections from immunosuppression.
• Medication toxicity – cyclophosphamide‑induced bladder cancer, azathioprine‑related liver injury, glucocorticoid‑induced osteoporosis, cataracts, hyperglycemia.
• Increased cardiovascular risk – chronic inflammation accelerates atherosclerosis.

When to Seek Emergency Care

Sources: 1. Mayo Clinic. Granulomatosis with polyangiitis. 2023. 2. CDC. Vasculitis surveillance data, 2022. 3. Kain et al. Nat Genet. 2021. 4. Harada et al. Ann Rheum Dis. 2020. 5. ACR/EULAR 2022 GPA classification criteria. 6. Rituximab for ANCA‑associated vasculitis: NEJM 2020. 7. Walsh et al. TMP‑SMX reduces relapse: J Rheumatol. 2022.